Physician profile
Andrew Perrotti
NPI 1134115801
$1,427.20
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $690 · 2020: $225 · 2021: $110 · 2022: $63.21 · 2023: $214 · 2024: $124.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $338.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $337.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $315.71 | 2019-2023 | Aptima |
| Abbvie INC. | $226.77 | 2019-2022 | |
| Baxter Healthcare | $106.20 | 2024 | Floseal |
| Myriad Women'S Health, INC. | $105.48 | 2023 | Myrisk |
| Amgen INC. | $98.96 | 2019-2020 | |
| Urocure LLC | $89.01 | 2021 | |
| Minerva Surgical, INC | $68.60 | 2020 | |
| Daiichi Sankyo INC. | $61.46 | 2019-2020 | |
| Pfizer INC. | $55.78 | 2019-2020 | |
| Amag Pharmaceuticals, INC. | $55.09 | 2019-2020 | |
| Allergan, INC. | $51.39 | 2019-2020 | |
| Avion Pharmaceuticals | $40.23 | 2019-2020 | |
| Astellas Pharma US INC | $32.65 | 2019-2020 | |
| Alydia Health | $21.44 | 2021 | |
| Organon LLC | $18.22 | 2024 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $17.40 | 2019 | |
| Radius Health, INC. | $16.68 | 2019 | |
| Therapeuticsmd, INC. | $16.34 | 2020 | |
| Mission Pharmacal Company | $15.90 | 2019 | |
| Lupin INC. | $13.89 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Perrotti listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.